SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

  • By Grand News Network
  • |
  • November 8, 2023

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alnylam Pharmaceuticals, Inc.:

On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients. Analysts commenting on the approval noted the FDA was not overly positive and "emphasized the small treatment effects and was seemingly negative on clinical meaningfulness." Following this news, Alnylam's stock price fell by $18.59 per share, or approximately 4% to close at $193.06 per share. Further, on October 9, 2023, Alnylam issued a press release announcing that the FDA issued a Complete Response ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner

More Stories